The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Open accessAbstract
The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT], or combined-modality therapy [CMT]) on outcomes of 148 LBCL patients who underwent leukapheresis for planned axicabtagene ciloleucel (axi-cel) infusion. The 55% (n = 81) of patients who received BT were more likely to have international prognostic index (IPI) score ≥3 (P ≤ .01), bulky disease (P = .01), and elevated lactate dehydrogenase (LDH; P ≤ .01). The 1-year progression-free (PFS) and overall survival (OS) rates were 40% and 65% in non-BT patients vs 21% and 48% in BT patients (P = .01 and .05, respectively). Twenty-four patients (16%) did not receive axi-cel, most commonly because of lymphoma progression (88%), despite 80% (n = 19) receiving BT. Among 124 patients who received axi-cel, 50% (n = 62) received BT with ST (n = 45), RT (n = 11), or CMT (n = 6); 1-year PFS and OS rates were not significantly different between BT and non-BT cohorts (P = .06 and .21, respectively). There was no difference in proportion of patients with IPI ≥3, limited-stage disease, or elevated LDH between ST, RT, and CMT groups. Compared with non-BT patients, 1-year PFS was inferior for ST-bridged patients (P = .01). RT-bridged patients had improved PFS compared with ST-bridged patients (P = .05). Despite the poor prognosis associated with requiring BT, RT can be an effective bridging strategy. Future studies are necessary to identify strategies that may improve access to CAR T-cell therapy and outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Self-citationLong-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Self-citationLocke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationNastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02104 · Cited by 801
Self-citation
Cited by
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116596 · Cited by 538
Self-citationBachy, E., Le Gouill, S., Di Blasi, R., Sesques, P., Manson, G., Cartron, G., Beauvais, D., Roulin, L., Gros, F. X., Rubio, M. T., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01969-y · Cited by 405
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 396
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Amini, L., Silbert, S. K., Maude, S. L., Nastoupil, L. J., Ramos, C. A., Brentjens, R. J., Sauter, C. S., Shah, N. N., & Abou-el-Enein, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00607-3 · Cited by 335
Self-citation
Metadata
- Authors
- Pinnix, C. C., Gunther, J. R., Dabaja, B. S., Strati, P., Fang, P., Hawkins, M. C., Adkins, S., Westin, J., Ahmed, S., Fayad, L., Lee, H. J., Nair, R., Steiner, R. E., Iyer, S. P., Rodriguez, M. A., Wang, M., Flowers, C., Neelapu, S. S., & Nastoupil, L. J.
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2020-06-26
- Volume
- 4
- Issue
- 13
- Pages
- 2871-2883
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- OpenAlex
- W3037322433
- Cited by
- 230
- References
- 5
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. https://app.cochat.ai/papers/10.1182/bloodadvances.2020001837
- The paper
- Pinnix, C. C., Gunther, J. R., Dabaja, B. S., Strati, P., Fang, P., Hawkins, M. C., Adkins, S., Westin, J., Ahmed, S., Fayad, L., Lee, H. J., Nair, R., Steiner, R. E., Iyer, S. P., Rodriguez, M. A., Wang, M., Flowers, C., Neelapu, S. S., & Nastoupil, L. J. (2020). Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Advances. https://doi.org/10.1182/bloodadvances.2020001837
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.